Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Subscribe To Our Newsletter & Stay Updated
